Samsung Bioepis and Genentech Settles Patent Dispute of SB8, a Proposed Biosimilar of Avastin
Shots:
- The companies have filed a joint stipulation of dismissal of their BPCIA patent litigation for the Avastin (bevacizumab) dispute. In June 2020, Genentech filed the suit against Samsung Bioepis alleging infringement of 14 patents related to bevacizumab
- Under the Settlement Agreement, the companies will voluntarily dismiss all claims & counterclaims in Avastin-related patent disputes allowing Samsung Bioepis’ biosimilar to be prescribed for all the same indications as reference drug
- The companies have ended 2yr. legal battle over the submission of marketing approval for SB8, an Avastin biosimilar in the US. SB8 will now be able to be prescribed to people with peritoneal cancer & epithelial ovarian cancer
Ref: Big Molecule Watch | Image: Genentech
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
